Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Pfizer Inc. is conducting a study titled Real World Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy Against RSV Illness in Infants. The study aims to evaluate the effectiveness of the ABRYSVO vaccine administered during pregnancy in preventing RSV-related illnesses in infants. This research is significant as it seeks to provide real-world data on the vaccine’s impact, potentially influencing public health strategies.
Intervention/Treatment: The study focuses on the ABRYSVO vaccine, a bivalent RSV prefusion F protein-based vaccine. It is designed to protect against both RSV-A and RSV-B strains, administered to pregnant individuals to safeguard infants from RSV-related complications.
Study Design: This observational study employs a retrospective case-control model. It uses three approaches: a test negative design, a descriptive cohort design, and an ecologic before-and-after design. The primary aim is to assess vaccine effectiveness and its impact on RSV-related outcomes in infants.
Study Timeline: The study began on August 26, 2024, with primary completion expected in 2025. The latest update was submitted on July 8, 2025. These dates are crucial as they mark the progression of the study and its ongoing status.
Market Implications: The study’s findings could significantly impact Pfizer’s stock performance and investor sentiment, especially if the results demonstrate strong vaccine effectiveness. This could position Pfizer favorably against competitors in the RSV vaccine market, potentially boosting its market share.
The study is ongoing, with further details available on the ClinicalTrials portal.